Skip to main content

Market Overview

BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study

Share:
BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study
  • BeiGene Ltd (NASDAQ: BGNE) has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental oxygen without mechanical ventilation.
  • The study did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen compared to placebo.
  • There were no new or additional safety signals for zanubrutinib identified in the trial.
  • BeiGene expects to submit these data for scientific presentation or publication in the future.
  • Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase (BTK).
  • Price Action: BGNE shares closed 2.3% lower at $321.60 on Wednesday.
 

Related Articles (BGNE)

View Comments and Join the Discussion!

Posted-In: Briefs Covid-19 Phase 2 TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com